{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:34:04Z","timestamp":1777584844984,"version":"3.51.4"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T00:00:00Z","timestamp":1266537600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2010,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy of 4.5mg nightly naltrexone on the quality of life of multiple sclerosis (MS) patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This single\u2010center, double\u2010masked, placebo\u2010controlled, crossover study evaluated the efficacy of 8 weeks of treatment with 4.5mg nightly naltrexone (low\u2010dose naltrexone, LDN) on self\u2010reported quality of life of MS patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Eighty subjects with clinically definite MS were enrolled, and 60 subjects completed the trial. Ten withdrew before completing the first trial period: 8 for personal reasons, 1 for a non\u2013MS\u2010related adverse event, and 1 for perceived benefit. Database management errors occurred in 4 other subjects, and quality of life surveys were incomplete in 6 subjects for unknown reasons. The high rate of subject dropout and data management errors substantially reduced the trial's statistical power. LDN was well tolerated, and serious adverse events did not occur. LDN was associated with significant improvement on the following mental health quality of life measures: a 3.3\u2010point improvement on the Mental Component Summary score of the Short Form\u201036 General Health Survey (<jats:italic>p<\/jats:italic> = 0.04), a 6\u2010point improvement on the Mental Health Inventory (<jats:italic>p<\/jats:italic> &lt; 0.01), a 1.6\u2010point improvement on the Pain Effects Scale (<jats:italic>p<\/jats:italic> =.04), and a 2.4\u2010point improvement on the Perceived Deficits Questionnaire (<jats:italic>p<\/jats:italic> = 0.05).<\/jats:p><\/jats:sec><jats:sec><jats:title>Interpretation<\/jats:title><jats:p>LDN significantly improved mental health quality of life indices. Further studies with LDN in MS are warranted. ANN NEUROL 2010<\/jats:p><\/jats:sec>","DOI":"10.1002\/ana.22006","type":"journal-article","created":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T14:58:01Z","timestamp":1266591481000},"page":"145-150","source":"Crossref","is-referenced-by-count":100,"title":["Pilot trial of low\u2010dose naltrexone and quality of life in multiple sclerosis"],"prefix":"10.1002","volume":"68","author":[{"given":"Bruce A. C.","family":"Cree","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Kornyeyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Goodin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,8,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2007.0051"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2006.05.005"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1369-1600.2008.00119.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01045.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458508095828"},{"key":"e_1_2_7_7_2","volume-title":"Multiple Sclerosis Quality of Life Inventory: a user's manual","author":"The Consortium of Multiple Sclerosis Centers Health Services Research Subcommittee","year":"1997"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.74.6.710"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/135245850000600508"},{"key":"e_1_2_7_12_2","volume-title":"The promise of naltrexone therapy. Potential benefits in cancer, autoimmune, neurological and infectious disease","author":"Moore E","year":"2008"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1191\/1352458502ms826oa"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-002-1446-5"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-510X(03)00225-9"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1997.00550240029009"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.57.10.1870"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.59.5.679"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1177\/135245859900500503"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.21163"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.22006","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.22006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T04:52:11Z","timestamp":1697518331000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.22006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["10.1002\/ana.22006"],"URL":"https:\/\/doi.org\/10.1002\/ana.22006","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}